Parkinson’s Disease and Cryptogenic Epilepsy

Table 1

Clinical and demographic characteristics.

	1	2	3	4	5
Age (years)	66	49	74	79	86
Sex	Male	Male	Male	Female	Female
Order of Dx	Epilepsy then PD	Epilepsy then PD	Epilepsy then PD	PD then epilepsy	PD then epilepsy
Epilepsy duration (years)	36	6	50	6	4
Type of seizures	Complex partial, GTC	Complex partial, secondarily generalized	Complex partial, GTC	Complex partial	Complex partial
PD duration (years)	10	1	1	15	10
UPDRS-III at PD Dx	9.5	10	21	28.5	26
H&Y stage at PD Dx	1	1	2.5	2.5	2.5
UPDRS-III at epilepsy Dx	N/A	N/A	N/A	27	21
H&Y stage at epilepsy Dx	N/A	N/A	N/A	2	2
UPDRS-III at last visit	51	23	20	51	36
H&Y stage at last visit	3	2	2.5	4	2
Most recent antiepileptic medication(s)	Eslicarbazepine	Carbamazepine and clonazepam	Carbamazepine	Levetiracetam and lamotrigine	Levetiracetam
Most recent LEDD (mg)	750	N/A	390	796	780

Dx, diagnosis; GTC, generalized tonic-clonic; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale; H&Y, Hoehn and Yahr; N/A, not applicable; LEDD, levodopa equivalent daily dose.